{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T12:11:40Z","timestamp":1785499900480,"version":"3.56.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T00:00:00Z","timestamp":1508112000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s11940-017-0479-9","type":"journal-article","created":{"date-parts":[[2017,10,15]],"date-time":"2017-10-15T22:26:34Z","timestamp":1508106394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Advances in the Treatment of Paraproteinemic Neuropathy"],"prefix":"10.1007","volume":"19","author":[{"given":"Eduardo","family":"Nobile-Orazio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Nozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,16]]},"reference":[{"key":"479_CR1","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1212\/WNL.31.11.1480","volume":"31","author":"JJ Kelly","year":"1981","unstructured":"Kelly JJ, Kyle RA, O\u2019Brien PC, Dyck PJ. Prevalence of monoclonal protein in peripheral neuropathy. Neurology. 1981;31:1480\u20133.","journal-title":"Neurology"},{"key":"479_CR2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1046\/j.1468-1331.2001.00187.x","volume":"8","author":"\u00c5 Mygland","year":"2001","unstructured":"Mygland \u00c5, Monstad P. Chronic polyneuropathies in Vest-Agder, Norway. Eur J Neurol. 2001;8:157\u201365.","journal-title":"Eur J Neurol"},{"key":"479_CR3","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362\u20139.","journal-title":"N Engl J Med"},{"key":"479_CR4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1529-8027.2010.00278.x","volume":"15","author":"Joint Task Force of the EFNS and the PNS","year":"2010","unstructured":"\u2022\u2022 Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies\/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society\u2014first revision. J Peripher Nerv Syst. 2010;15:185\u201395. This not so recent guideline is still one of the most important revision on the diagnosis and treatment of paraproteinemic neuropathies.","journal-title":"J Peripher Nerv Syst"},{"key":"479_CR5","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1600-0404.1992.tb06033.x","volume":"85","author":"E Nobile-Orazio","year":"1992","unstructured":"Nobile-Orazio E, Barbieri S, Baldini L, Marmiroli P, Carpo M, Premoselli S, et al. Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies. Acta Neurol Scand. 1992;85:383\u201390.","journal-title":"Acta Neurol Scand"},{"key":"479_CR6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0022-510X(93)90297-C","volume":"114","author":"M Vrethem","year":"1993","unstructured":"Vrethem M, Cruz M, Wen-Xin H, Malm C, Holmgren H, Ernerudh J. Clinical, neurophysiological and immunological evidence of polyneuropathy in patients with monoclonal gammopathies. J Neurol Sci. 1993;114:193\u20139.","journal-title":"J Neurol Sci"},{"issue":"36","key":"479_CR7","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/ana.410360313","volume":"1994","author":"E Nobile-Orazio","year":"1994","unstructured":"Nobile-Orazio E, Manfredini E, Carpo M, Meucci N, Monaco S, Ferrari S, et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol. 1994;1994(36):416\u201324.","journal-title":"Ann Neurol"},{"issue":"8","key":"479_CR8","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/ajh.24802","volume":"92","author":"A Dispenzieri","year":"2017","unstructured":"\u2022\u2022 Dispenzieri A. POEMS syndrome: 2017 update on diagnosis, risk stratification, and management. Am J Hematol. 2017;92(8):814\u201329. This is an excellent and updated review on the diagnosis, pathogenesis, and therapy of POEMS syndrome.","journal-title":"Am J Hematol"},{"key":"479_CR9","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/(SICI)1097-4598(199811)21:11<1390::AID-MUS5>3.0.CO;2-4","volume":"21","author":"O Watanabe","year":"1998","unstructured":"Watanabe O, Maruyama I, Arimura K, Kitajima I, Arimura H, Hanatani M, et al. Overproduction of vascular endothelial growth factor\/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. Muscle Nerve. 1998;21:1390\u20137.","journal-title":"Muscle Nerve"},{"key":"479_CR10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/mus.10182","volume":"26","author":"JY Sung","year":"2002","unstructured":"Sung JY, Kuwabara S, Ogawara K, Kanai K, Hattori T. Patterns of nerve conduction abnormalities in POEMS syndrome. Muscle Nerve. 2002;26:189\u201393.","journal-title":"Muscle Nerve"},{"key":"479_CR11","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.clinph.2004.11.011","volume":"116","author":"JH Min","year":"2005","unstructured":"Min JH, Hong YH, Lee KW. Electrophysiological features of patients with POEMS syndrome. Clin Neurophysiol. 2005;116:965\u20138.","journal-title":"Clin Neurophysiol"},{"issue":"5","key":"479_CR12","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/jnnp-2011-301706","volume":"83","author":"S Nasu","year":"2012","unstructured":"Nasu S, Misawa S, Sekiguchi Y, Shibuya K, Kanai K, Fujimaki Y, et al. Different neurological and physiological profiles in POEMS syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 2012;83(5):476\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"479_CR13","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/B978-0-444-52902-2.00025-4","volume-title":"Handbook of clinical neurology. Vol. 115 (3rd series); Peripheral nerve disorders","author":"E Nobile-Orazio","year":"2013","unstructured":"Nobile-Orazio E. Neuropathy and monoclonal gammopathy. In: Said G, Krarup C, editors. Handbook of clinical neurology. Vol. 115 (3rd series); Peripheral nerve disorders, vol. 115. Amsterdam: Elsevier BV; 2013. p. 443\u201359."},{"issue":"1","key":"479_CR14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1529-8027.2012.00376.x","volume":"17","author":"K Viala","year":"2012","unstructured":"Viala K, Stojkovic T, Doncker AV, Maisonobe T, Lenglet T, Bruneteau G, et al. Heterogeneous spectrum of neuropathies in Waldenstr\u00f6m\u2019s macroglobulinemia: a diagnostic strategy to optimize their management. J Peripher Nerv Syst. 2012;17(1):90\u2013101.","journal-title":"J Peripher Nerv Syst"},{"key":"479_CR15","first-page":"301","volume":"3","author":"N Latov","year":"1988","unstructured":"Latov N, Hays AP, Sherman WH. Peripheral neuropathy and anti-MAG antibodies. Crit Rev Neurobiol. 1988;3:301\u201332.","journal-title":"Crit Rev Neurobiol"},{"key":"479_CR16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/ajh.2830450105","volume":"45","author":"L Baldini","year":"1994","unstructured":"Baldini L, Nobile-Orazio E, Guffanti A, Barbieri S, Carpo M, Cro L, et al. Peripheral neuropathy in IgM monoclonal gammopathy and Waldenstr\u00f6m Macroglobulinemia: a frequent complication in males with low MAG-reactive serum monoclonal component. Am J Hematol. 1994;45:25\u201331.","journal-title":"Am J Hematol"},{"key":"479_CR17","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/ana.410260408","volume":"26","author":"E Nobile-Orazio","year":"1989","unstructured":"Nobile-Orazio E, Francomano E, Daverio R, Barbieri S, Marmiroli P, Manfredini E, et al. Anti-myelin-associated glycoprotein IgM antibody titers in neuropathy associated with macroglobulinemia. Ann Neurol. 1989;26:543\u201350.","journal-title":"Ann Neurol"},{"key":"479_CR18","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.33.7.939","volume":"33","author":"E Nobile-Orazio","year":"1983","unstructured":"Nobile-Orazio E, Vietorisz T, Messito MJ, Sherman W, Latov N. Anti-MAG IgM antibodies in patients with neuropathy and IgM M-proteins: detection by ELISA. Neurology. 1983;33:939\u201342.","journal-title":"Neurology"},{"key":"479_CR19","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1212\/WNL.0b013e3181b59a80","volume":"73","author":"ML Kuijf","year":"2009","unstructured":"Kuijf ML, Eurelings M, Tio-Gillen AP, van Doorn PA, van den Berg LH, Hooijkaas H, et al. Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy. Neurology. 2009;73:688\u201395.","journal-title":"Neurology"},{"key":"479_CR20","doi-asserted-by":"publisher","first-page":"450391","DOI":"10.1155\/2015\/450391","volume":"2015","author":"L Magy","year":"2015","unstructured":"\u2022 Magy L, Kabor\u00e9 R, Mathis S, Lebeau P, Ghorab K, Caudie C, et al. Heterogeneity of polyneuropathy associated with anti-MAG antibodies. J Immunol Res. 2015;2015:450391. \nhttps:\/\/doi.org\/10.1155\/2015\/450391\n\n. In this recent study, the authors measured the levels of anti-MAG antibodies using the Buhlman assay and compared the titer of the antibodies with the clinical and pathological features of the neuropathy.","journal-title":"J Immunol Res"},{"key":"479_CR21","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/brain\/123.4.710","volume":"123","author":"E Nobile-Orazio","year":"2000","unstructured":"Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relation with immune therapies. Brain. 2000;123:710\u20137.","journal-title":"Brain"},{"key":"479_CR22","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1212\/WNL.0b013e3181ccc6b9","volume":"74","author":"JM Niermeijer","year":"2010","unstructured":"Niermeijer JM, Fischer K, Eurelings M, Franssen H, Wokke JH, Notermans NC. Prognosis of polyneuropathy due to IgM monoclonal gammopathy. Neurology. 2010;74:406\u201312.","journal-title":"Neurology"},{"key":"479_CR23","first-page":"CD002827","volume":"10","author":"MP Lunn","year":"2016","unstructured":"\u2022\u2022 Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev. 2016;10:CD002827. This very recent review analyzes the effect of immune therapies in anti-MAG neuropathy and shows that, by combining the results of two small negative studies, rituximab proves to be indeed effective in this neuropathy.","journal-title":"Cochrane Database Syst Rev"},{"key":"479_CR24","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJM199111213252105","volume":"325","author":"PJ Dyck","year":"1991","unstructured":"Dyck PJ, Low PA, Windebank AJ, Jaradeh SS, Gosselin S, Bourque P, et al. Plasmaexhange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med. 1991;325:1482\u20136.","journal-title":"N Engl J Med"},{"issue":"3","key":"479_CR25","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/jnnp.59.3.243","volume":"59","author":"E Oksenhendler","year":"1995","unstructured":"Oksenhendler E, Chevret S, L\u00e9ger JM, Louboutin JP, Bussel A, Brouet JC. Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry. 1995;59(3):243\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"479_CR26","doi-asserted-by":"publisher","unstructured":"Codron P, Cousin M, Subra JF, Pautot V, Letournel F, Verny C, et al. Therapeutic plasma exchange in chronic dysimmune peripheral neuropathies: a 10-year retrospective study. J Clin Apher. 2017; \nhttps:\/\/doi.org\/10.1002\/jca.21530\n\n.","DOI":"10.1002\/jca.21530"},{"issue":"6","key":"479_CR27","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1007\/s00415-017-8502-3","volume":"264","author":"M Baron","year":"2017","unstructured":"\u2022 Baron M, Lozeron P, Harel S, Bengoufa D, Vignon M, Asli B, et al. Plasma exchanges for severe acute neurological deterioration in patients with IgM anti-myelin-associated glycoprotein (anti-MAG) neuropathy. J Neurol. 2017;264(6):1132\u20135. This interesting study analyzed the effect of plasmaexchange in four patients with anti-MAG neuropathy and an acute neurological deterioration who improved with this therapy.","journal-title":"J Neurol"},{"issue":"10","key":"479_CR28","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1007\/s00415-002-0808-z","volume":"249","author":"G Comi","year":"2002","unstructured":"Comi G, Roveri L, Swan A, Willison H, Bojar M, Illa I, et al. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol. 2002;249(10):1370\u20137.","journal-title":"J Neurol"},{"issue":"5","key":"479_CR29","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ana.410400516","volume":"40","author":"MC Dalakas","year":"1996","unstructured":"Dalakas MC, Quarles RH, Farrer RG, Dambrosia J, Soueidan S, Stein DP, et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol. 1996;40(5):792\u20135.","journal-title":"Ann Neurol"},{"issue":"1","key":"479_CR30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/jnnp.63.1.28","volume":"63","author":"X Mariette","year":"1997","unstructured":"Mariette X, Chastang C, Clavelou P, Louboutin JP, Leger JM, Brouet JC. A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry. 1997;63(1):28\u201334.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"479_CR31","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1136\/jnnp.69.2.279","volume":"69","author":"X Mariette","year":"2000","unstructured":"Mariette X, Brouet JC, Chevret S, Leger JM, Clavelou P, Pouget J, et al. A randomised double blind trial versus placebo does not confirm the benefit of alpha-interferon in polyneuropathy associated with monoclonal IgM. J Neurol Neurosurg Psychiatry. 2000;69(2):279\u201380.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"479_CR32","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1212\/01.wnl.0000265055.28218.cc","volume":"69","author":"JM Niermeijer","year":"2007","unstructured":"Niermeijer JM, Eurelings M, van der Linden MW, Lokhorst HM, Franssen H, Fischer K, et al. Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy. Neurology. 2007;69(1):50\u20139.","journal-title":"Neurology"},{"key":"479_CR33","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jns.2017.04.015","volume":"377","author":"S Gazzola","year":"2017","unstructured":"Gazzola S, Delmont E, Franques J, Boucraut J, Salort-Campana E, Verschueren A, et al. Predictive factors of efficacy of rituximab in patients with anti-MAG neuropathy. J Neurol Sci. 2017;377:144\u20138.","journal-title":"J Neurol Sci"},{"issue":"1\u20132","key":"479_CR34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jns.2014.11.006","volume":"348","author":"Y Kawagashira","year":"2015","unstructured":"\u2022 Kawagashira Y, Koike H, Ohyama K, Hashimoto R, Iijima M, Adachi H, et al. Axonal loss influences the response to rituximab treatment in neuropathy associated with IgM monoclonal gammopathy with anti-myelin-associated glycoprotein antibody. J Neurol Sci. 2015;348(1\u20132):67\u201373. In this study, the authors report a correlation between clinical improvement after therapy with rituximab and the short duration of the disease and the preservation of fiber density on nerve biopsy in patients with anti-MAG neuropathy.","journal-title":"J Neurol Sci"},{"issue":"6","key":"479_CR35","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00277-014-2294-7","volume":"94","author":"G Talamo","year":"2015","unstructured":"Talamo G, Mir MA, Pandey MK, Sivik JK, Raheja D. IgM MGUS associated with anti-MAG neuropathy: a single institution experience. Ann Hematol. 2015;94(6):1011\u20136.","journal-title":"Ann Hematol"},{"key":"479_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2015.02.009","volume":"281","author":"M Campagnolo","year":"2015","unstructured":"Campagnolo M, Ferrari S, Dalla Torre C, Cabrini I, Cacciavillani M, Lucchetta M, et al. Polyneuropathy with anti-sulfatide and anti-MAG antibodies: clinical, neurophysiological, pathological features and response to treatment. J Neuroimmunol. 2015;281:1\u20134.","journal-title":"J Neuroimmunol"},{"key":"479_CR37","doi-asserted-by":"publisher","unstructured":"\u2022 Campagnolo M, Zambello R, Nobile-Orazio E, Benedetti L, Marfia GA, Riva N, et al. IgM MGUS and Waldenstr\u00f6m-associated anti-MAG neuropathies display similar risposte to rituximab therapy. J Neurol Neurosurg Psychiatry. 2017; \nhttps:\/\/doi.org\/10.1136\/jnnp-2017-315736\n\n. In this study, the authors reported a comparable response to rituximab in patients with anti-MAG antibodies associated with either MGUS or Waldenstr\u00f6m\u2019s macroglobulinemia.","DOI":"10.1136\/jnnp-2017-315736"},{"key":"479_CR38","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jns.2016.12.029","volume":"373","author":"PE Doneddu","year":"2017","unstructured":"Doneddu PE, Kazmi M, Samuel M, Mahdi-Rogers M, Hadden RD. Deterioration of tremor after treatment with rituximab in anti-MAG neuropathy. J Neurol Sci. 2017;373:344\u20135.","journal-title":"J Neurol Sci"},{"key":"479_CR39","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ana.21577","volume":"65","author":"MC Dalakas","year":"2009","unstructured":"\u2022 Dalakas MC, Rakocevic G, Salajegheh M, Dambrosia JM, Hahn AF, Raju R, et al. Placebo controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol. 2009;65:286\u201393. This not so recent randomized controlled study first showed that rituximab may have some effects in anti-MAG neuropathy even if the results were only derived by the exclusion of an erroneously included patient.","journal-title":"Ann Neurol"},{"issue":"24","key":"479_CR40","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1212\/WNL.0b013e318296e92b","volume":"80","author":"JM L\u00e9ger","year":"2013","unstructured":"\u2022 L\u00e9ger JM, Viala K, Nicolas G, Cr\u00e9ange A, Vallat JM, Pouget J, et al. Placebo controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology. 2013;80(24):2217\u201325. This negative controlled study on the effect of rituximab in anti-MAG neuropathy shows that the therapy may improve some parameters and, combined with the previous study, permits to show that the therapy is indeed effective in this neuropathy.","journal-title":"Neurology"},{"key":"479_CR41","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1212\/01.wnl.0000335268.70325.33","volume":"71","author":"L Benedetti","year":"2008","unstructured":"Benedetti L, Briani C, Franciotta D, Carpo M, Padua L, Zara G, et al. Long-term effect of rituximab in anti-MAG polyneuropathy. Neurology. 2008;71:1742\u20134.","journal-title":"Neurology"},{"issue":"1","key":"479_CR42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/jns.12156","volume":"21","author":"R Iancu Ferfoglia","year":"2016","unstructured":"Iancu Ferfoglia R, Guimar\u00e3es-Costa R, Viala K, Musset L, Neil J, Marin B, et al. Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study. J Peripher Nerv Syst. 2016;21(1):10\u20134.","journal-title":"J Peripher Nerv Syst"},{"key":"479_CR43","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1529-8027.2011.00343.x","volume":"16","author":"B Gruson","year":"2011","unstructured":"Gruson B, Ghomari K, Beaumont M, Garidi R, Just A, Merle P, et al. Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy. J Peripher Nerv Syst. 2011;16:180\u20135.","journal-title":"J Peripher Nerv Syst"},{"issue":"7","key":"479_CR44","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.clml.2016.04.004","volume":"16","author":"A Gomez","year":"2016","unstructured":"Gomez A, Hoffman JE. Anti myelin-associated-glycoprotein antibody peripheral neuropathy response to combination chemoimmunotherapy with bendamustine\/rituximab in a patient with biclonal IgM k and IgM \u03bb: case report and review of the literature. Clinical Lymphoma, Myeloma & Leukemia. 2016;16(7):e101\u20138.","journal-title":"Clinical Lymphoma, Myeloma & Leukemia"},{"issue":"6","key":"479_CR45","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2015-01-553974","volume":"126","author":"SP Treon","year":"2015","unstructured":"\u2022 Treon SP. How I treat Waldenstr\u00f6m macroglobulinemia. Blood. 2015;126(6):721\u201332. This is a well done and updated hematological review on the treatment of Waldenstr\u00f6m\u2019s macroglobulinemia.","journal-title":"Blood"},{"key":"479_CR46","doi-asserted-by":"publisher","unstructured":"Stino AM, Efebera Y. Lenalidomide-responsive anti-myelin-associated glycoprotein neuropathy. Muscle Nerve. 2017; \nhttps:\/\/doi.org\/10.1002\/mus.25709\n\n.","DOI":"10.1002\/mus.25709"},{"key":"479_CR47","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","volume":"113","author":"KR Carson","year":"2009","unstructured":"Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, et al. Progressive multifocal leukoencephalopathy following rituximab therapy in HIV negative patients: a report of 57 cases from the Research on Adverse Drug Event and Reports project. Blood. 2009;113:4834\u201340.","journal-title":"Blood"},{"issue":"18","key":"479_CR48","doi-asserted-by":"crossref","first-page":"E3689","DOI":"10.1073\/pnas.1619386114","volume":"114","author":"R Herrendorff","year":"2017","unstructured":"\u2022\u2022 Herrendorff R, H\u00e4nggi P, Pfister H, Yang F, Demeestere D, Hunziker F, et al. Selective in vivo removal of pathogenic anti-MAG autoantibodies, an antigen-specific treatment option for anti-MAG neuropathy. Proc Natl Acad Sci U S A. 2017;114(18):E3689\u201398. This excellent study addresses the possibility to perform a selective antigen-specific treatment in patients with anti-MAG neuropathy.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1\u20132","key":"479_CR49","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jneuroim.2014.01.012","volume":"268","author":"AC Stork","year":"2014","unstructured":"Stork AC, Jacobs BC, Tao-Gillen AP, Nurslings M, Jansen MD, van den Berg LH, et al. Prevalence, specificity and functionality of anti-ganglioside antibodies in neuropathy associated with IgM monoclonal gammopathy. J Neuroimmunol. 2014;268(1\u20132):89\u201394.","journal-title":"J Neuroimmunol"},{"key":"479_CR50","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jns.2007.09.020","volume":"266","author":"E Nobile-Orazio","year":"2008","unstructured":"Nobile-Orazio E, Gallia F, Terenghi F, Allaria S, Giannotta C, Carpo M. How useful are anti-neural IgM antibodies in the diagnosis of chronic immune-mediated neuropathies? J Neurol Sci. 2008;266:156\u201363.","journal-title":"J Neurol Sci"},{"key":"479_CR51","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/ene.12658","volume":"22","author":"C Giannotta","year":"2015","unstructured":"Giannotta C, Di Pietro D, Gallia F, Nobile-Orazio E. Anti-sulfatide IgM antibodies in peripheral neuropathy: to test or not to test? Eur J Neurol. 2015;22:879\u201382.","journal-title":"Eur J Neurol"},{"key":"479_CR52","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1093\/brain\/124.10.1968","volume":"124","author":"HJ Willison","year":"2001","unstructured":"Willison HJ, O\u2019Leary CP, Veitch J, Blumhardt LD, Busby M, Donaghy M, et al. The clinical and laboratory features of chronic sensory ataxic demyelinating neuropathy with anti-disialosyl IgM antibodies. Brain. 2001;124:1968\u201377.","journal-title":"Brain"},{"key":"479_CR53","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s00415-008-0803-0","volume":"255","author":"R Rojas-Garcia","year":"2008","unstructured":"Rojas-Garcia R, Gallardo E, Povedano M, de Luna N, Bruna J, Juarez C, et al. Antibodies against disialosyl and terminal NeuNAc (\u03b12-3)Gal ganglioside epitopes in acute relapsing sensory ataxic neuropathy. J Neurol. 2008;255:764\u20136.","journal-title":"J Neurol"},{"key":"479_CR54","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/jnnp.2008.157065","volume":"80","author":"R Ahdab","year":"2009","unstructured":"Ahdab R, Lefaucheur JP, Malapert D, Touze E, Caudie C, Andr\u00e9 C, et al. Neuropathy with anti-disialosyl IgM antibodies and multifocal persistent motor conduction blocks. J Neurol Neurosurg Psychiatry. 2009;80:700\u20132.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"479_CR55","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/jnnp.2009.185736","volume":"81","author":"S Attarian","year":"2010","unstructured":"Attarian S, Boucraut J, Hubert AM, Uzenot D, Delmont E, Verschueren A, et al. Chronic ataxic neuropathies associated with anti-GD1b IgM antibodies: response to IVIg therapy. J Neurol Neurosurg Psychiatry. 2010;81:61\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"479_CR56","first-page":"CD005376","volume":"24","author":"AC Stork","year":"2015","unstructured":"\u2022\u2022 Stork AC, Lunn MPT, Nobile-Orazio E, Notermans NC. Treatment for IgG and IgA paraproteinemic neuropathy. Cochrane Database Syst Rev. 2015;24(3):CD005376. This is an updated review on the treatment of neuropathies associated with IgG or IgA paraproteinemia.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"479_CR57","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/ajh.23810","volume":"89","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV. Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89(10):999\u20131009.","journal-title":"Am J Hematol"},{"key":"479_CR58","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/PL00007853","volume":"249","author":"S Quasthoff","year":"2002","unstructured":"Quasthoff S, Hartung HP. Chemotherapy induced peripheral neuropathy. J Neurol. 2002;249:9\u201317.","journal-title":"J Neurol"},{"issue":"5","key":"479_CR59","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/WCO.0000000000000234","volume":"28","author":"G Cavaletti","year":"2015","unstructured":"Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Curr Opin Neurol. 2015;28(5):500\u20137.","journal-title":"Curr Opin Neurol"},{"key":"479_CR60","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-319-40320-5_1","volume":"169","author":"MV Mateos","year":"2016","unstructured":"Mateos MV, Landgren O. MGUS and smoldering multiple myeloma: diagnosis and epidemiology. Cancer Treat Res. 2016;169:3\u201312.","journal-title":"Cancer Treat Res"},{"key":"479_CR61","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ana.410300111","volume":"30","author":"S Gosselin","year":"1991","unstructured":"Gosselin S, Kyle RA, Dyck PJ. Neuropathy associated with monoclonal gammopathies of undetermined significance. Ann Neurol. 1991;30:54\u201361.","journal-title":"Ann Neurol"},{"key":"479_CR62","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/BF00319857","volume":"238","author":"KB Yeung","year":"1991","unstructured":"Yeung KB, Thomas PK, King RHM, Waddy H, Will RG, Hughes RA, et al. The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings. J Neurol. 1991;238:383\u201391.","journal-title":"J Neurol"},{"key":"479_CR63","first-page":"979","volume":"158","author":"E Nobile-Orazio","year":"2002","unstructured":"Nobile-Orazio E, Casellato C, Di Troia A. Neuropathies associated with IgG and IgA monoclonal gammopathy. Rev Neurol (Paris). 2002;158:979\u201387.","journal-title":"Rev Neurol (Paris)"},{"key":"479_CR64","first-page":"139","volume":"1","author":"E Hermosilla","year":"1996","unstructured":"Hermosilla E, Lagueny A, Vital C, Vital A, Ferrer X, Steck A, et al. Peripheral neuropathy associated with monoclonal IgG of undetermined significance: clinical, electrophysiologic, pathologic and therapeutic study of 14 cases. J Peripher Nerv Sys. 1996;1:139\u201348.","journal-title":"J Peripher Nerv Sys"},{"key":"479_CR65","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0022-510X(99)00049-0","volume":"164","author":"A Troia Di","year":"1999","unstructured":"Di Troia A, Carpo M, Meucci N, Pellegrino C, Allaria S, Gemignani F, et al. Clinical features and anti-neural reactivity in neuropathy associated with IgG monoclonal gammopathy of undetermined significance. J Neurol Sci. 1999;164:64\u201371.","journal-title":"J Neurol Sci"},{"key":"479_CR66","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jns.2004.02.020","volume":"221","author":"MM Mehndiratta","year":"2004","unstructured":"Mehndiratta MM, Sen K, Tatke M, Bajaj BK. IgA monoclonal gammopathy of undetermined significance with peripheral neuropathy. J Neurol Sci. 2004;221:99\u2013104.","journal-title":"J Neurol Sci"},{"key":"479_CR67","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/1531-8249(200006)47:6<808::AID-ANA15>3.0.CO;2-8","volume":"47","author":"JM Vallat","year":"2000","unstructured":"Vallat JM, Tabaraud F, Sindou P, Preux PM, Vandenberghe A, Steck A. Myelin widenings and MGUS-IgA: an immunoelectron microscopic study. Ann Neurol. 2000;47:808\u201311.","journal-title":"Ann Neurol"},{"key":"479_CR68","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1440-1789.2008.00875.x","volume":"28","author":"A Vital","year":"2008","unstructured":"Vital A, Nedelec-Ciceri C, Vital C. Presence of cristalline inclusions in the peripheral nerve of a patient with IgA lambda monoclonal gammopathy of undetermined significance. Neuropathology. 2008;28:526\u201331.","journal-title":"Neuropathology"},{"issue":"8","key":"479_CR69","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","volume":"346","author":"RA Kyle","year":"2002","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564\u20139.","journal-title":"N Engl J Med"},{"issue":"2","key":"479_CR70","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/(SICI)1097-4598(200002)23:2<164::AID-MUS4>3.0.CO;2-Y","volume":"23","author":"S Ponsford","year":"2000","unstructured":"Ponsford S, Willison H, Veitch J, Morris R, Thomas PK. Long-term clinical and neurophysiological follow-up of patients with peripheral, neuropathy associated with benign monoclonal gammopathy. Muscle Nerve. 2000;23(2):164\u201374.","journal-title":"Muscle Nerve"},{"key":"479_CR71","first-page":"CD010369","volume":"1","author":"AL Oaklander","year":"2017","unstructured":"Oaklander AL, Lunn MPT, Hughes RAC, van Schaik IN, Frost C, Chalk CH. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews (review). Cochrane Database Syst Rev. 2017;1:CD010369.","journal-title":"Cochrane Database Syst Rev"},{"key":"479_CR72","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1182\/blood-2002-07-2299","volume":"101","author":"A Dispenzieri","year":"2003","unstructured":"Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Therneau TM, Larson DR, et al. POEMS syndrome: definitions and long-term out come. Blood. 2003;101:2496\u2013506.","journal-title":"Blood"},{"issue":"6","key":"479_CR73","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/ajh.24356","volume":"91","author":"TV Kourelis","year":"2016","unstructured":"\u2022 Kourelis TV, Buadi FK, Kumar SK, Gertz MA, Lacy MQ, Dingli D, et al. Long-term outcome of patients with POEMS syndrome: an update of the Mayo Clinic experience. Am J Hematol. 2016;91(6):585\u20139. In this study, the authors reviewed the effect of treatment in a large series of patients with POEMS syndrome followed at their institution.","journal-title":"Am J Hematol"},{"key":"479_CR74","first-page":"CD006828","volume":"6","author":"S Kuwabara","year":"2012","unstructured":"Kuwabara S, Dispenzieri A, Arimura K, Misawa S, Nakaseko C. Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. Cochrane Database Syst Rev. 2012;6:CD006828.","journal-title":"Cochrane Database Syst Rev"},{"key":"479_CR75","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/blood-2013-03-487025","volume":"122","author":"MS Humeniuk","year":"2013","unstructured":"Humeniuk MS, Gertz MA, Lacy MQ, Kyle RA, Witzig TE, Kumar SK, et al. Outcomes of patients with POEMS syndrome treated initially with radiation. Blood. 2013;122:66\u201373.","journal-title":"Blood"},{"key":"479_CR76","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/leu.2015.344","volume":"30","author":"TV Kourelis","year":"2016","unstructured":"Kourelis TV, Buadi FK, Gertz MA, Lacy MQ, Kumar SK, Kapoor P, et al. Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment. Leukemia. 2016;30:1079\u201385.","journal-title":"Leukemia"},{"key":"479_CR77","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1182\/blood-2010-12-328112","volume":"117","author":"J Li","year":"2011","unstructured":"Li J, Zhang W, Jiao L, Duan MH, Guan HZ, Zhu WG, et al. Combination of melphalan and dexamethasonefor patients with newly diagnosed POEMS syndrome. Blood. 2011;117:6445\u20139.","journal-title":"Blood"},{"key":"479_CR78","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1600-0609.2008.01037.x","volume":"80","author":"A Dispenzieri","year":"2008","unstructured":"Dispenzieri A, Lacy MQ, Hayman SR, Kumar SK, Buadi F, Dingli D, et al. Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. Eur J Haematol. 2008;80:397\u2013406.","journal-title":"Eur J Haematol"},{"key":"479_CR79","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1212\/01.wnl.0000188757.38495.23","volume":"66","author":"S Kuwabara","year":"2006","unstructured":"Kuwabara S, Misawa S, Kanai K, Kikkawa Y, Nishimura M, Nakaseko C, et al. Autologous peripheral blood stem cell transplantation for POEMS syndrome. Neurology. 2006;66:105\u20137.","journal-title":"Neurology"},{"key":"479_CR80","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1212\/01.wnl.0000323811.42080.a4","volume":"71","author":"S Kuwabara","year":"2008","unstructured":"Kuwabara S, Misawa S, Kanai K, Suzuki Y, Kikkawa Y, Sawai S, et al. Neurologic improvement after peripheral blood stem cell transplantation in POEMS syndrome. Neurology. 2008;71:1691\u20135.","journal-title":"Neurology"},{"key":"479_CR81","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.nmd.2007.05.004","volume":"17","author":"F Giglia","year":"2007","unstructured":"Giglia F, Chiapparini L, Farisell L, Barbui T, Ciano C, Scarlato M, et al. POEMS syndrome: relapse after successful autologous peripheral blood stem cell transplantation. Neuromuscul Disord. 2007;17:980\u20132.","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"479_CR82","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.nmd.2009.07.001","volume":"19","author":"S Kuwabara","year":"2009","unstructured":"Kuwabara S, Kanai K, Misawa S, Nakaseko C. Relapse of POEMS syndrome without increased level of VEGF. Neuromuscul Disord. 2009;19(10):740.","journal-title":"Neuromuscul Disord"},{"key":"479_CR83","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/ajh.20051","volume":"76","author":"M Sinisalo","year":"2004","unstructured":"Sinisalo M, Hietaharju A, Sauranen J, Wirta O. Thalidomide in POEMS: case report. Am J Hematol. 2004;76:66\u20138.","journal-title":"Am J Hematol"},{"key":"479_CR84","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/jnnp.2008.150177","volume":"79","author":"S Kuwabara","year":"2008","unstructured":"Kuwabara S, Misawa S, Kanai K, Sawai S, Hattori T, Nishimura M, et al. Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome. J Neurol Neurosurg Psychiatry. 2008;79:1255\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"479_CR85","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2169\/internalmedicine.49.2833","volume":"49","author":"D Inoue","year":"2010","unstructured":"Inoue D, Kato A, Tabata S, Kitai T, Takiuchi Y, Kimura T, et al. Successful treatment of POEMS syndrome complicated by severe congestive heart failure with thalidomide. Intern Med. 2010;49:461\u20136.","journal-title":"Intern Med"},{"key":"479_CR86","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S1474-4422(16)30157-0","volume":"15","author":"S Misawa","year":"2016","unstructured":"\u2022\u2022 Misawa S, Sato Y, Katayama K, Nagashima K, Aoyagi R, Sekiguchi Y, et al. Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2016;15:1129\u201337. This is the first randomized controlled study performed in POEMS syndrome showing that thalidomide is effective in reducing serum VEGF levels even if it does not induce a significant clinical improvement.","journal-title":"Lancet Neurol"},{"key":"479_CR87","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood-2007-03-082354","volume":"110","author":"A Dispenzieri","year":"2007","unstructured":"Dispenzieri A, Klein CJ, Mauermann ML. Lenalidomide therapy in a patient with POEMS syndrome. Blood. 2007;110:1075\u20136.","journal-title":"Blood"},{"key":"479_CR88","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1097\/SMJ.0b013e3181b2f7d8","volume":"102","author":"S Sethi","year":"2009","unstructured":"Sethi S, Tageja N, Arabi H, Penumetcha R. Lenalidomide therapy in a rare case of POEMS syndrome with kappa restriction. South Med J. 2009;102:1092\u20133.","journal-title":"South Med J"},{"key":"479_CR89","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3324\/haematol.2011.041897","volume":"97","author":"JF Tom\u00e1s","year":"2012","unstructured":"Tom\u00e1s JF, Giraldo P, Lecumberri R, Nistal S. POEMS syndrome with severe neurological damage clinically recovered with Lenalidomide. Haematologica. 2012;97:320\u20132.","journal-title":"Haematologica"},{"key":"479_CR90","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/ajh.23374","volume":"88","author":"B Royer","year":"2012","unstructured":"Royer B, Merlusca L, Abraham J, Musset L, Haroche J, Choquet S, et al. Efficacy of Lenalidomide in POEMS syndrome: a retrospective study of 20 patients. Am J Hematol. 2012;88:207\u20132012.","journal-title":"Am J Hematol"},{"key":"479_CR91","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/ajh.23195","volume":"87","author":"B Vannata","year":"2012","unstructured":"Vannata B, Laurenti L, Chiusolo P, Sor\u00e0 F, Balducci M, Sabatelli M, et al. Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem-cell transplantation. Am J Hematol. 2012;87:641\u20132.","journal-title":"Am J Hematol"},{"key":"479_CR92","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.3109\/10428194.2013.869329","volume":"55","author":"F Zagouri","year":"2014","unstructured":"\u2022 Zagouri F, Kastritis E, Gavriatopoulou M, Sergentanis TN, Psaltopoulou T, Terpos E, et al. Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis. Leuk Lymphoma. 2014;55:2018\u201323. This is a well done review on the effect of lenalidomide in previously reported patients with POEMS.","journal-title":"Leuk Lymphoma"},{"key":"479_CR93","doi-asserted-by":"crossref","unstructured":"Nozza A, Terenghi F, Gallia F, Adami F, Briani C, Merlini G, et al. Lenalidomide and dexamethasone in patients with poems syndrome: results of a prospective, open-label trial. Br J Haematol. 2017. in press.","DOI":"10.1111\/bjh.14966"},{"issue":"supplement","key":"479_CR94","first-page":"244","volume":"22","author":"M Bianco","year":"2017","unstructured":"Bianco M, Terenghi F, Gallia F, Nozza A, Scarale A, Fayoumi MZ, et al. Comparison of two-year response to lenalidomide or peripheral blood stem-cell transplantation in patients with POEMS. J Peripher Nerv Syst. 2017;22(supplement):244.","journal-title":"J Peripher Nerv Syst"},{"issue":"12","key":"479_CR95","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1136\/jnnp-2012-304874","volume":"84","author":"Y Sekiguchi","year":"2013","unstructured":"Sekiguchi Y, Misawa S, Shibuya K, Nasu S, Mitsuma S, Iwai Y, et al. Ambiguous effects of anti-VEGF monoclonal antibody (bevacizumab) for POEMS syndrome. J Neurol Neurosurg Psychiatry. 2013;84(12):1346\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"479_CR96","doi-asserted-by":"publisher","unstructured":"He H, Fu W, Du J, Jiang H, Hou J. Successful treatment of newly diagnosed POEMS syndrome with reduced-dose bortezomib based regimen. Br J Haematol. 2017; \nhttps:\/\/doi.org\/10.1111\/bjh.14497\n\n.","DOI":"10.1111\/bjh.14497"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-017-0479-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-017-0479-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-017-0479-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,12,5]],"date-time":"2017-12-05T23:19:43Z","timestamp":1512515983000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-017-0479-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,16]]},"references-count":96,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["479"],"URL":"https:\/\/doi.org\/10.1007\/s11940-017-0479-9","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,16]]},"article-number":"43"}}